Investor Relations
at Nutriband Inc.
COMPANY PROFILE
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
INDUSTRY CLASSIFICATIONS
Sector: Health Care
Industry: Industrial Specialties
Nutriband’s Mission to Address the Opioid Crisis Through Innovation
Nutriband Inc. is committed to fight the global opioid epidemic by advancing abuse-deterrent transdermal drug delivery technologies. Each year, fentanyl and other opioid medications are linked to thousands of preventable overdose deaths.
Through our subsidiary, 4P Therapeutics, we’ve developed our patented AVERSA™ abuse deterrent transdermal technology designed to reduce the potential for abuse and misuse of transdermal opioid patches. We believe AVERSA™ has the potential to ensure that pain patients who require treatment with transdermal opioids can continue to get the access they need.
👉 View our latest investor presentation here to learn more about our technology, regulatory pathway, and strategic vision.
